ELRIG UK Announces
Steve Bates and Dr Anderson Ryan as Keynote Speakers at Research and Innovation 2024
- ELRIG Research and Innovation 2024 takes place from 20–21 March in Manchester, UK
- Key topics include oncology, antimicrobial resistance, mass spectrometry, proteomics and animal-free drug discovery
- Launch of TechBio Breakthrough Zone offers young companies an opportunity to showcase innovations
- Award available to early career professionals making an impact on the community
Cambridge, UK, 08 February 2024: The European Laboratory Research & Innovation Group (ELRIG) UK today announced the keynote speakers for its upcoming Research and Innovation conference taking place at the University of Manchester from 20–21 March. Steve Bates OBE FMedSci CEO, BioIndustry Association (BIA) and Dr Anderson Ryan, Co-founder and Head of R&D and Drug Development, FasT BioPharma will lead this year’s event which will focus on accelerating drug discovery.
This free-to-attend event will bring together scientists, researchers and entrepreneurs to discuss how emerging biology and innovative technologies are pioneering the medicines of tomorrow and helping to enable the next generation of therapeutics. It will comprise four main sessions covering animal-free technologies, oncology drug discovery, tackling antimicrobial resistance as well as advances in mass spectrometry techniques and proteomics. There will also be a trade show and exhibition, a poster competition, and a host of networking opportunities.
Steve Bates leads the BIA, the UK’s trade association for innovative life science companies. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia, and is committed to next-generation talent and developing the skills needed for the sector to flourish. He serves on the UK Government’s Life Sciences Council and Vaccine Taskforce as well as the UK Biosecurity Leadership Council. Steve has helped enable effective industrial incentives, like the Biomedical Catalyst, and forged links for the sector across the USA, Europe and China. Before joining the BIA, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair. He was appointed an OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.
Dr Anderson Ryan is the scientific co-founder of FasT BioPharma, an oncology-focussed start-up, where he leads the R&D programme. Prior to this he served as VP Head of Oncology at Mission Therapeutics, Head of Translational Science at Medicines Discovery Catapult and worked in a number of roles at AstraZeneca, including leading translational science programmes across a broad range of preclinical and clinical oncology indications. Anderson was previously a lecturer in cancer studies at the University of Manchester, and Associate Professor and Senior MRC Group Leader in the Department of Oncology at the University of Oxford, investigating new therapeutic approaches in lung cancer. He has trained more than 20 post-graduate students, published over 200 scientific papers and 12 patents, and acts as an oncology/drug-development reviewer for key funders, including CRUK, UKRI and Innovate UK.
ELRIG will be launching the TechBio Breakthrough Zone at Research and Innovation 2024. The new exhibition space provides young companies with the opportunity to present their technology and connect with potential customers and collaborators. There is also an opportunity to nominate early-career professionals for ELRIG’s Impact Award which will recognise an individual for their scientific contribution and its impact on early-stage drug discovery.
Sarah Brockbank, Conference Director, ELRIG UK and Strategy Leader—Complex Medicines, Medicines Discovery Catapult, said: “We have an outstanding line up of speakers covering key focus areas in drug discovery and development. These world-leading experts will share their insights and experiences on the challenges and opportunities in the field, and we are honoured to have Steve Bates and Dr Anderson Ryan on board as keynote speakers.”
Roger Clark, Conference Director, ELRIG UK and Head of High Throughput Screening, Charles River Laboratories, said: “We look forward to welcoming scientists from academia and industry to the University of Manchester, celebrating its bicentenary this year — the perfect setting to share bold ideas to accelerate future drug discovery and reflect upon the transformative achievements that have paved the way for new generation therapeutics.”
Steve Bates OBE FMedSci, CEO, BioIndustry Association, said: “I’m delighted to be speaking at ELRIG Research and Innovation this year. The event presents an excellent opportunity for the vibrant life sciences industry to connect, collaborate and discuss the latest innovations. This is vital to the success of the community as we strive towards the discovery and development of new medicines to cure more patients around the world.”
Dr Anderson Ryan, Co-founder and Head of R&D and Drug Development, FasT BioPharma: “The organisers have put together a terrific line up packed with interesting talks, poster presentations, exhibitors and networking opportunities. I’m proud to be presenting at such an exciting event, providing researchers and entrepreneurs with a host of opportunities to discover emerging biology and cutting-edge technologies, including those from young companies.”
For further information about Research and Innovation 2024, please visit: https://elrig.org/portfolio/research-innovation-2024/
ELRIG UK Establishes Engagement Strategy Work Group
Group aims to improve access to scientific programmes and grow ELRIG community
Cambridge, UK, 14 September 2023: The European Laboratory Research & Innovation Group (ELRIG) UK today announced the formation of its Engagement Strategy Work Group (ESWG). The group will provide strategic direction and guidance to help ensure the ELRIG community continues to grow and thrive. It aims to engage audiences in different ways, beyond face-to-face events, broadening access to high-quality science across a more diverse and inclusive network.
ELRIG is a not-for-profit, volunteer-led community, comprising a diverse global network of over 22,000 life science professionals from biopharma, CRO’s, academia or with vendor companies. ELRIG aims to bring the life science and drug discovery communities together to learn, share, connect, innovate, and collaborate, on an open-access basis through the provision of conferences, networking events, webinars, and digital content. The board delegates its tasks to a series of work groups, who work with the ELRIG team to ensure it achieves these objectives.
The ESWG will focus on developing and implementing a cohesive digital content strategy, social media presence and media partnerships, improving accessibility and inclusivity, and
creating additional value from its scientific content. It will make key recommendations that support the strategic pillars of the organization and strive to ensure that the perspectives of all its community members are considered and represented in discussion and decisions.
Dr Chris Williams, ELRIG Board Member and Founder & Managing Director, Questae Coaching & Consulting, will lead the ESWG. She has over 20 years’ experience in the pharmaceutical industry having worked at Pfizer, UCB, Ipsen and the NHS demonstrating a breadth of scientific, project, business, and change management experience. Dr Williams will be supported by ELRIG’s Sanj Kumar, CEO, and Emily Norman, Marketing & Communications Manager, and volunteers from across the scientific community: Abby George, Senior Content Editor at BioStrata; Alison Rawlinson, Head of Marketing at Qkine; Kayvan Richter, Research Communications and Marketing Manager at Cancer Research UK; Dr Michelle Ricketts, Managing Director at Codon Communications; and Dr Sophie Rose, Head of Business Development, Europe at Metrion Biosciences.
“Driven by the philosophy of sustainability and accessibility, we want to make sure that our scientific content can be reached by those not able to attend our events. Whilst not being there in person means people don’t benefit from the spontaneity and networking that happens, we want to promote access and digital connectivity to enhance application of scientific and technological innovations wherever you are. We are aiming to provide platforms for scientific exchange that resonate whether you are an early career professional, academic, entrepreneur or pharma/biotech leader. This mentality has provoked the change to a more strategic look at different ways to engage our community through the ESWG,” said Dr Chris Williams, Engagement Strategy Work Group Lead, ELRIG UK, and Founder & Managing Director, Questae Coaching & Consulting.
“As ever, we are truly thankful to our volunteer members who have stepped forward to join this team and are open to other applications from those who believe they can bring these philosophies to life across our community,” she added.
The formation of the ESWG follows the reorganization of ELRIG’s governance and work group structure earlier this year which saw Saleha Patel, Associate Principal Scientist, Emerging Innovations, Discovery Sciences, R&D at AstraZeneca, selected as Chair of Scientific Programme Work Group, and Nick Clare, Interim Chief Business Officer and VP of Strategic Alliances at DefiniGEN, appointed as Vendor Strategy Work Group Lead.
Emily Norman, Marketing & Communications Manager, ELRIG UK, said: “We are passionate about engaging our members in the high-quality content we provide and committed to delivering complementary scientific programmes that are relevant and respond to the needs of our diverse network. The newly formed Engagement Strategy team will work alongside all ELRIG’s Work Groups to improve access to the scientific content from our conferences and networking events through digital platforms, publications, and media partnerships, as well as promote inclusivity, collaboration, and sustainability. In doing so, we hope to widen our reach into the life sciences community, attracting new members to our events and into the ELRIG organization.”
For further information about ELRIG’s Work Groups, please visit:
https://elrig.org/workgroups/ or meet the team at Drug Discovery 2023 taking place in Liverpool, UK from 18–19 October.
Notes to Editors
|Dr Chris Williams, Engagement Strategy Work Group Lead, ELRIG UK, and
Founder & Managing Director, Questae Coaching & Consulting
|Emily Norman, Marketing & Communications Manager, ELRIG UK
|ELRIG UK’s Engagement Strategy Work Group. Left to right: (first row) Sanj Kumar, Emily Norman, Dr Chris Williams, Kayvan Richter, (second row) Dr Sophie Rose, Dr Michelle Ricketts, Alison Rawlinson, Abby Edwards
Please contact Codon Communications for high-resolution images.
Tel: +44 7860 892944
Dr Michelle Ricketts
Tel: +44 7789 053885